Drug intelligence / Profile preview

SSTA-152

Development stage: Preclinical
Lead developer: StemSynergy Therapeutics
Modality: Small Molecules

Overview

SSTA-152 (also referred to as SSTK-152) is a preclinical-stage small molecule developed by StemSynergy Therapeutics. It is designed to target and potentially degrade Myc family proteins, specifically c-Myc and N-Myc, which are transcription factors frequently overexpressed or dysregulated in a wide range of human cancers. By reducing the levels or activity of these proteins, SSTA-152 aims to inhibit the growth and survival of c-Myc- and N-Myc-driven malignancies. The program is currently in preclinical development for the treatment of various Myc-driven cancers.

Targets

Myc proto-oncogene protein at the MYC:Aurora kinase A interfaceMYCN (N-myc proto-oncogene protein)

Beyond the preview

Go deeper on SSTA-152.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SSTA-152.

Explore the full profile